By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1055 E. Colorado Boulevard. Fifth Floor

Pasadena  California  91106  U.S.A.
Phone: 323-721-5500 Fax: 323-721-9131


Company News
Confidential Data From Genervon ALS Phase IIA Clinical Trial Were Released And Published 3/23/2017 8:20:53 AM
Genervon Release: Company Reveals ALS, PD And AD Disease-Associated Gene Lists Modulated By GM6 And Encourages Researchers To Explore New Discoveries Beyond Single Target Drug Development Paradigm 1/10/2017 11:31:33 AM
Genervon Release: ALS And Alzheimer’s Disease Bioinformatics Reports Confirm GM6’s Role As Regulator Of Disease-Relevant Pathways 12/27/2016 10:28:15 AM
Genervon Release: GM604 To Be Granted "Orphan Drug" Status In Europe 5/3/2016 9:24:27 AM
Genervon GM604 Reduced TDP-43 Protein Aggregates And Slowed Down ALS Progression 9/22/2015 10:48:04 AM
Genervon Filed Patent For Using GM604 Modulations Of ALS Disease Biomarkers Showing Homeostasis, Leading To Prognosis And Therapeutic Treatment For ALS Disease 6/29/2015 10:39:54 AM
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation 4/21/2015 6:52:00 AM
Genervon Announces ALS Compassionate Use Results 1/8/2015 10:56:03 AM
Genervon Announces ALS And PD Phase 2a Trial Results 10/20/2014 9:29:21 AM
Genervon Announces Biomarker Data From GALS-001 Clinical Trial For ALS 6/30/2014 10:53:40 AM